Phaseline

Companies › Alpine Immune Sciences

Alpine Immune Sciences: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 3; Immunology, Genitourinary; next expected readout Jan 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Povetacicept (ALPN-303)
Dual CD27/CD70 co-stimulation inhibitor
CD27, CD70Phase 3Immunoglobulin A NephropathyJan 2028
Povetacicept (ALPN-303)
CD27 costimulatory molecule inhibitor
CD27Phase 1Lupus NephritisMar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06564142Povetacicept (ALPN-303)Phase 3Immunoglobulin A NephropathyGenitourinaryJan 2028
NCT05732402Povetacicept (ALPN-303)Phase 1Lupus NephritisImmunologyMar 2028

Targets

CD27 (2) CD70 (1)

Companies with the same targets

Chongqing Precision Biotech Allogene Therapeutics Xilio Development Pfizer Beijing Biotech OncoVerity Qilu Pharmaceutical Hrain Biotechnology Adicet Therapeutics

Companies built like this

Climb Bio RAPT Therapeutics, Inc., a member of the GSK plc group of companies Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Chengdu Kangnuoxing Biopharma AnaptysBio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.